andere Bezeichnungen
- Encephalomyelitis disseminata (ED)
Multiple Sklerose (MS)
Die multiple Sklerose ist eine chronisch-entzündliche Erkrankung, bei der die Markscheiden (= Myelinscheiden = elektrisch isolierende äußere Schicht der Nervenfasern) im zentralen Nervensystem (ZNS) angegriffen sind.
Hauptwirksame Cannabinoide
- CBD (Cannabidiol)
- CBDa
- CBN
- Δ⁹-THC
- Δ⁹-THCa
Studien/Artikel zur Behandlung von Multiple Sklerose (MS) mit Cannabis-Medikation
- Does the cannabinoid dronabinol reduce central pain in multiple sclerosis? Randomised double blind placebo controlled crossover trial.
- The effect of cannabis on tremor in patients with multiple sclerosis.
- Sativex for the management of multiple sclerosis symptoms.
- THC and CBD oromucosal spray (Sativex®) in the management of spasticity associated with multiple sclerosis.
- THC/CBD oromucosal spray in patients with multiple sclerosis overactive bladder: a pilot prospective study.
- Effect of tetrahydrocannabinol:cannabidiol oromucosal spray on activities of daily living in multiple sclerosis patients with resistant spasticity: a retrospective, observational study.
- Clinical efficacy and effectiveness of Sativex, a combined cannabinoid medicine, in multiple sclerosis-related spasticity.
- Cannabidiol provides long-lasting protection against the deleterious effects of inflammation in a viral model of multiple sclerosis: a role for A2A receptors.
- Pain Modulation after Oromucosal Cannabinoid Spray (SATIVEX®) in Patients with Multiple Sclerosis: A Study with Quantitative Sensory Testing and Laser-Evoked Potentials.
- Oromucosal delta9-tetrahydrocannabinol/cannabidiol for neuropathic pain associated with multiple sclerosis: an uncontrolled, open-label, 2-year extension trial.
- Nabiximols in the treatment of spasticity, pain and urinary symptoms due to multiple sclerosis.
- Sativex long-term use: an open-label trial in patients with spasticity due to multiple sclerosis.
- A double-blind, randomized, placebo-controlled, parallel-group study of Sativex, in subjects with symptoms of spasticity due to multiple sclerosis.
- Meta-analysis of cannabis based treatments for neuropathic and multiple sclerosis-related pain.
- Cannabis and cognitive functioning in multiple sclerosis: The role of gender.
- Sativex: clinical efficacy and tolerability in the treatment of symptoms of multiple sclerosis and neuropathic pain.
- Evaluating Sativex® in Neuropathic Pain Management: A Clinical and Neurophysiological Assessment in Multiple Sclerosis.
- Target regulation of PI3K/Akt/mTOR pathway by cannabidiol in treatment of experimental multiple sclerosis.
- Tetrahydrocannabinol:Cannabidiol Oromucosal Spray for Multiple Sclerosis-Related Resistant Spasticity in Daily Practice.
- The effect of cannabinoids on the stretch reflex in multiple sclerosis spasticity.
- Sativex® as Add-on therapy Vs. further optimized first-line ANTispastics (SAVANT) in resistant multiple sclerosis spasticity: a double-blind, placebo-controlled randomised clinical trial.
- (-)-β-Caryophyllene, a CB2 Receptor-Selective Phytocannabinoid, Suppresses Motor Paralysis and Neuroinflammation in a Murine Model of Multiple Sclerosis.
- Link Wikipedia (DE)
sonstiges Wissenswertes
BfArM Ausnahmgenehmigungen erteilt (vor der Gesetzesänderung im März 2017 in Deutschland gab es für Multiple Sklerose (MS) Diagnosen Ausnahmegenehmigungen zur Behandlung mit Cannabis durch das Bundesinstitut für Arzneimittel und Medizinprodukte)
1 Kommentare